EN DE
Watch CareDx Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

CareDx Inc (CDNA) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of CareDx Inc stock $13.95, price $78.56, that is 82.2% below the price, quality 71 out of 100. Rating: strongly overvalued. Calculated from audited financials with 7 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

CI CareDx Inc logo Thin data Nov 6, 2026

CareDx Inc

CDNA · US
Solid, but very expensive

Our calculation puts a fair price 82% below what the stock costs today.

Quality 71/100
Highly profitable · 25.9% net margin (TTM)
Low debt
Generates free cash flow
Positive coverage
Revenue last quarter +39% vs. a year ago.
Mixed Growth (revenue 5y +14.6 %/yr in USD)
Mixed vs. peers (5/12)
Moderate moat 56/100 · thin data
Insiders sold $12.1M (6M)
Fair value $13.95 · Strongly overvalued (−82.2%)
Thin data
Extreme value
Watch CareDx Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$88.47 $4.90 Fair Value $13.95 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $4.90 – $88.47 · fair‑value band $8.70 – $23.65 · the $78.56 price screens above the $13.95 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 6, 2026.

Follow CareDx in your weekly email

Every Wednesday you see whether CareDx is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.

Show moreShow less

The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.

It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes.

In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software.

Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions.

It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014.

The company was incorporated in 1998 and is headquartered in Brisbane, California.

Stock analysis

CareDx Inc (CDNA) currently trades at $78.56, while our model-based Fair Value estimate is $13.95, 82% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $15.06 per share, and 0 of the 7 models we run sit above the $78.56 price.

Bear case: the Asset-Based group reads lowest at $2.84, and 7 of the 7 models stay below the price. Data coverage for this calculation is low.

Scenario range: $8.70 (bear) to $23.65 (bull), the price of $78.56 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 71/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

CareDx Inc reported revenue of $380M in FY2025 versus $296M in FY2021, a compound +6.4%/yr. Reported net income was −$21.4M in FY2025.

Key figures

Market cap $4.2B Mid · P/E ratio 37.8 · P/S ratio 8.44 · EPS (TTM) $2.08 · Net margin 25.9% · Return on equity 33.0% · Return on assets (EBIT) −12.0% (5-year average) · Operating margin 5.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 56 out of 100 (low confidence).

What moves the price

The share trades about 11% below its 52-week high and 423% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −82%, CDNA screens richer than that median.

Fair Value models

Bear $8.70 Fair Value $13.95 Bull $23.65
Price $78.56 · Downside -82.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($1.78 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $10.14 $13.95 $25.13 78
Growth DCF $9.55 $14.60 $23.65 77
5Y Revenue Exit $8.42 $13.68 $24.32 70
All 7 models by family
DCF Models
FCF DCF $10.14 $13.95 $25.13 78
5Y Revenue Exit $8.42 $13.68 $24.32 70
10Y Revenue Exit $8.70 $16.12 $21.89 66
Multiples
EV/Revenue $7.11 $9.83 $12.56 54
Asset-Based
NCAV (Graham) $1.88 $2.84 $3.55 55
Growth DCF
Growth DCF $9.55 $14.60 $23.65 77
Rev-Margin DCF $8.42 $15.52 $26.59 70

Open the full fair value analysis →

Quality Score breakdown

Overall quality 71/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 33
How much profit the company makes from its sales and capital
Quality Growth 62
Are margins and returns getting better?
Cashflow 60
Do the profits arrive as real cash?
Financial strength 87
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 100
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 93
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 7 officers or directors sold shares worth $12.1M and none bought.

  • SaleGeorge BickerstaffDirector20,000 shares at $46.29$925,800Aug 5, 2026
  • SaleJeffrey Adam NovackSecretary and General Counsel4× since Dec 4, 2025: 17,110 shares, avg. $24.03$411,079Aug 5, 202610b5-1 plan
  • SaleChristine CournoyerDirector16,000 shares at $46.94$751,040Aug 4, 202610b5-1 plan
  • SaleMichael GoldbergDirector44,700 shares at $47.06$2.1MAug 4, 2026
  • SaleJohn Walter Hanna JRPresident and CEO, Director8× since Jan 15, 2026: 242,434 shares, avg. $31.10$7.5MJul 16, 202610b5-1 plan
  • SaleHannah ValantineDirector2× since Jun 15, 2026: 40,882 shares, avg. $32.28$1.3MJul 16, 202610b5-1 plan
  • SaleArthur A TorresDirector10,570 shares at $20.31$214,650May 15, 2026

Plus 26 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 91/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+13.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.6%
Start year 2020 (pandemic). Over 10 years: +29.7% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−11.7% (2020) → −5.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+51.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+12.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +47.9% a year for the price and +9.4% for the forecasts.
Forecast 2026 (sales)+35.6%
Forecast 2027 (sales)+7.9%
Projected 2028 (sales)+7.1%
Projected 2029 (sales)+6.4%
Projected 2030 (sales)+5.7%

CDNA screens overvalued: fair value 82% below the price. Compare with Thermo Fisher Scientific Inc →

Earlier news

News mood ⓘNews mood, the average tone of recent news (98 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.
Note from the team Oct 11, 2026
AI conclusion: High gross margins in transplant diagnostics are offset by negative profitability and low ROE amid limited durable evidence.
Main risk: Integration challenges with the Naveris acquisition and contingent revenue targets could pressure profitability in the expanded oncology testing business.
CareDx has narrowed its focus to transplant diagnostics and cell therapy after selling its lab products business and acquiring Naveris for oncology testing. Favorable Medicare LCD outcomes strengthen reimbursement for the core allograft monitoring tests, yet integrating the new platform and meeting contingent revenue targets introduce clear execution hurdles. Do the transplant tailwinds more than offset the integration risks in the expanded oncology business?
Join the discussion →

Compare CareDx Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks

Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 71 · Top 25%
Fair Value upside −82.2% · Bottom 25%
Profitability
Return on equity (12 months) 33.0% · Top 25%
Return on assets −5.2% · Below median
Net margin (12 months) 25.9% · Top 25%
Operating margin (12 months) 5.8% · Below median
Growth and dividend
Revenue growth (quarter YoY) 39.3% · Top 25%
Balance sheet
Debt / equity 0.06× · Below median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/E (12 months) 37.8× · Pricier than median
P/B 13.85× · Priciest 25%
P/S (12 months) 8.44× · Priciest 25%
Price / free cash flow (fiscal year) 116.2× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 39
PAST (return on equity)100 · sector 15
HEALTH (low debt)97 · sector 95
DIVIDEND (yield)0 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥147.00 ¥164.66 +12% vs CDNA
IQVIA Holdings IQV $271.83 $299.01 +10% vs CDNA
Illumina, Inc ILMN $213.13 $228.80 +7% vs CDNA
Thermo Fisher Scientific Inc TMO $694.76 $686.04 −1% vs CDNA
Danaher Corporation DHR $230.25 $209.18 −9% vs CDNA
IDEXX Laboratories, Inc IDXX $676.04 $496.48 −27% vs CDNA
Mettler-Toledo International Inc MTD $1,722 $650.28 −62% vs CDNA
Agilent Technologies, Inc A $174.76 $64.53 −63% vs CDNA
Lonza Group LONN CHF 663.40 CHF 153.50 −77% vs CDNA
Waters Corporation WAT $457.60 $91.26 −80% vs CDNA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CareDx Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "CareDx Inc Fair Value". https://www.fairvalue-calculator.com/stock/CDNA

Frequently asked questions

Is CareDx Inc (CDNA) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $13.95 versus a price of $78.56, about 82% lower (overvalued).
What is the fair value of CDNA?
Our model-based fair value for CareDx Inc is $13.95 (as of Nov 6, 2026), built from audited fundamentals. The current price: $78.56.
What is the quality score of CDNA?
CareDx Inc has a Quality Score of 71/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CareDx Inc (CDNA)?
Our model-based price target is the fair value of $13.95 (as of Nov 6, 2026) from 7 valuation models. Cautious scenario $8.70, optimistic scenario $23.65. It is a calculation from audited fundamentals, not an analyst target.
What is the CareDx Inc stock forecast for 2026?
Our models put fair value at $13.95, about 82% lower versus a price of $78.56 (overvalued). Cautious scenario $8.70, optimistic scenario $23.65. The calculation is refreshed regularly with new filings.
What is the revenue of CareDx Inc (CDNA)?
CareDx Inc reported trailing-twelve-month revenue of about $497M (latest available figure, as of Nov 6, 2026).
What growth is priced into CareDx Inc (CDNA)?
For today's price to be fair in a discounted-cash-flow model, CareDx Inc would have to grow free cash flow by +51.4 % per year for five years (discount rate 12.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +14.6 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of CDNA use?
Our models discount CareDx Inc at 12.2 %: a base by market capitalisation (mid), damped by beta 2.38, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For CareDx Inc that is +51.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.2 %) and the same formula as our fair value.
How much growth has CareDx Inc (CDNA) delivered so far?
Over the past 5 years revenue at CareDx Inc grew +14.6 % a year. The price currently implies free-cash-flow growth of +51.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of CareDx Inc (CDNA) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into CareDx Inc (+51.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of CareDx Inc (CDNA)?
The free-cash-flow yield on the price is 0.86 %: that much free cash flow CareDx Inc produces per unit of market value. When it exceeds the discount rate of our models (12.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of CareDx Inc (CDNA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CareDx Inc it is $13.95 per share (as of Nov 6, 2026), against a price of $78.56. It is the blended result of 7 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is CareDx Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, CDNA trades above its calculated fair value: price $78.56, fair value $13.95, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CDNA?
No. The price is what the market pays today ($78.56); the fair value is what the company's own numbers justify ($13.95). For CareDx Inc the two are $64.61 per share apart. That gap is exactly why we show both numbers side by side.
How much is CareDx Inc worth?
The market values CareDx Inc at about $4.2B (market capitalisation, as of Nov 6, 2026). Per share that is $78.56; our models calculate a fair value of $13.95 per share.
What do the bullish and bearish scenarios say about CDNA?
Our models span a range for CareDx Inc: cautious scenario $8.70, base $13.95, optimistic $23.65 per share (as of Nov 6, 2026, price $78.56). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CDNA?
CareDx Inc trades at a price-to-earnings ratio of 37.8 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $13.95 is built from several models across several years. Other multiples: P/B 13.9, P/S 8.4.
How solid is the balance sheet of CareDx Inc (CDNA)?
Balance-sheet figures for CareDx Inc (as of Nov 6, 2026): return on equity 33.0%, debt of 0.06 per unit of equity. They feed the Quality Score of 71/100, which measures business quality independently of the share price.
How far is CDNA from its 52-week high?
CareDx Inc trades at $78.56, about 11% below its 52-week high of $88.47 and 423% above the low of $15.01 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $13.95 is for.
Which stocks are comparable to CareDx Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CareDx Inc stock attractive at the current price?
The data as of Nov 6, 2026: price $78.56, calculated fair value $13.95 (−82%), Quality Score 71/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CDNA calculated?
We run CareDx Inc through 7 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of $13.95 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. CareDx Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CareDx Inc (CDNA)?
The closing price on Nov 6, 2026 was $78.56. Our model-based fair value is $13.95, about 82% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CareDx Inc right now?
The price sits above even our optimistic bull case ($23.65). The favourable scenario is already priced in. The model range is unusually wide ($8.70 to $23.65). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (71/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of CareDx Inc

How large is the market capitalisation of CareDx Inc (CDNA)?
The market capitalisation of CareDx Inc is $4.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CareDx Inc (CDNA)?
The price-to-sales ratio of CareDx Inc is 8.44 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CareDx Inc (CDNA)?
Earnings per share at CareDx Inc are $2.08 (price ÷ EPS = P/E 37.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of CareDx Inc (CDNA)?
The net margin of CareDx Inc is 25.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CareDx Inc (CDNA)?
The return on equity (ROE) of CareDx Inc is 33.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CareDx Inc (CDNA)?
On an EBIT basis the return on assets of CareDx Inc is −12.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CareDx Inc (CDNA)?
The operating margin of CareDx Inc is 5.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CareDx Inc (CDNA)?
Revenue at CareDx Inc is growing +39.3% versus a year earlier (3y avg +5.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at CareDx Inc (CDNA)?
Earnings per share at CareDx Inc are growing +10.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does CareDx Inc (CDNA) hold?
CareDx Inc holds more cash than debt, $39.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch CareDx Inc in the live analysis

One click puts CareDx Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.